The efficacy of 2EF against several tumor models, its capacity to reach deeply seated cancer sites and its lack of toxicity in animal models support 2EF as a novel candidate and an efficient anti-Trop-2 therapeutic mAb. This evidence concerns the gene TACSTD2 and neoplasm.